Efrain Gaxiola

TL;DR: A verapamil SR-based antihypertensive treatment strategy is an alternative to a &bgr;-blocker–based strategy in adults with CAD and diabetes and resulted in similar rates of cardiovascular outcomes in coronary artery disease (CAD) patients with diabetes.

TL;DR: The Hispanic cohort of INVEST had better blood pressure control and lower risk of adverse cardiovascular outcomes compared with the non-Hispanic cohort, and a verapamil SR strategy is an alternative to an atenolol strategy for the treatment of Hispanic patients with hypertension and CAD and can reduce the risk of new-onset diabetes.

TL;DR: In hypertensive patients with CAD, increased risk for adverse outcomes was associated with conditions related to the severity of CAD and diminished left ventricular function, and lower follow-up BP and addition of trandolapril to verapamil SR each were associated with reduced risk.

TL;DR: The hypothesis that platelet glycoprotein IIb/IIIa inhibitors play a key role not only in the atherothrombosis process, but also in the disturbances of microcirculation and tissue perfusion is supported.

TL;DR: The paclitaxel-eluting TAXUS slow-release stent exhibits long-term safety and efficacy in uncomplicated and higher risk patients and lesions seen in everyday clinical practice.